Personalising screening, monitoring and treatment choices when the most common female cancer in Hong Kong is not one disease.
Hong Kong context In 2023 the Hong Kong Cancer Registry recorded 5,603 new breast cancer cases, making it the second most common cancer overall and the leading cancer in women (5,585 female cases). Incidence has risen sharply over the past decade. |
Why this cancer is hard to manage with a single protocol
Breast cancer is treated as if it were a single diagnosis, yet hormone-receptor status, HER2 status, Ki-67, BRCA and other germline findings, and the growing group of triple-negative tumours all behave differently. Two women with the same stage can need opposite strategies.
Standard follow-up leans on mammography, ultrasound, MRI and serum markers such as CA15-3 or CEA. Those tools miss micrometastatic activity in blood. They also cannot tell a clinician, in advance, whether a particular anthracycline, taxane, platinum, CDK4/6 inhibitor, or a natural compound is likely to drive apoptosis in that patient’s circulating tumour cells.
After surgery or during adjuvant therapy, the practical question is often not “is there a mass on the scan?” but “are viable tumour cells still circulating, how stem-like are they, and what are they sensitive to now?”
What circulating tumor cells add
Circulating tumour cells are cancer cells that have left the primary site and entered the bloodstream. In breast cancer they can be detected even when imaging is quiet. Serial CTC counts, phenotype markers and stemness markers give a live view of residual disease, aggressiveness and the risk that a clone is shifting phenotype — for example losing hormone-receptor expression or gaining stem-like features.
Oncotrail RGCC is built for confirmed breast cancer. It enumerates CTCs and immunophenotypes them with markers relevant to breast tumours, rather than a generic panel. RGCC sample reports use a breast-specific reference range to help the clinician read whether the count sits in an early / responding band or an advanced / progressing band.
When the question is “what should we use next?”, Onconomics Plus cultures isolated CTCs and tests a broad list of chemotherapeutic agents, targeted drugs and natural substances, and reports gene-expression and resistance markers (including efflux pumps such as MDR1 / MRP / LRP). That is the difference between choosing a protocol from a guideline chapter and choosing a protocol from the cells that are actually circulating in that woman.
The RGCC pathway for this cancer
A typical sequence is screening or baseline first, then a comprehensive profile when treatment choices matter, then serial follow-up. The exact panel is chosen by the accredited practitioner.
Clinical question | RGCC test to consider |
No diagnosis, wants earlier signal than imaging alone | Onco-D-clare — gene-expression screening of peripheral blood mononuclear cells with machine-learning classification |
Confirmed breast cancer; set a baseline or monitor treatment / remission | Oncotrail RGCC — breast-specific CTC count, phenotype and activity markers |
Need to choose chemo, targeted agents or natural compounds | Onconomics Plus — ex-vivo sensitivity plus gene-expression and resistance markers |
Quick interval check of burden only | Oncocount — CTC presence and concentration |
Pharmacogenomic safety of a planned drug | ChemoSNiP — inherited variants that affect drug handling |
Immune status before an integrative plan | Immune-Frame |
What the report can change in practice
A falling CTC count with quieter stemness markers during treatment is one way to see that the current plan is landing. A rising count, or a shift in phenotype, is a reason to restage and reconsider — including whether the cells have become resistant to the agent in use.
Onconomics Plus does not invent a new drug. It ranks agents the team already has access to, including agents that guidelines list as options but does not rank for that individual. For hormone-positive disease it can sit beside endocrine therapy decisions. For HER2-positive disease it sits beside anti-HER2 choices. For triple-negative disease — where options are narrower and recurrence risk is higher — a functional sensitivity profile is often the most useful page in the file.
Natural-substance results (Onconomics Extracts, included in Plus) are not a substitute for oncology. They are a structured way for an integrative practitioner to stop guessing which extracts are even active against that patient’s CTCs.
Who this article is for
• Women with a new breast cancer diagnosis who want a baseline before systemic treatment.
• Patients already on adjuvant or metastatic treatment whose scans and markers are mixed or inconclusive.
• Triple-negative or heavily pre-treated disease, where the next line is not obvious.
• People in remission who want a blood-based surveillance tool between imaging appointments.
• Adults without a diagnosis but with strong family history or personal concern, as a screening conversation around Onco-D-clare — not as a replacement for mammography.
Next step
Book a 30-minute discussion with an RGCC-accredited practitioner. Bring your pathology report (ER / PR / HER2 / Ki-67, any NGS) and a treatment timeline. The practitioner will map which test belongs at this step — screening, Oncotrail baseline, or Onconomics Plus — and how the result will be used with your oncologist.
Disclaimer. This article is educational and is intended for patients, families, and referring practitioners. RGCC tests are laboratory investigations that support clinical decision-making. They do not replace imaging, tissue diagnosis, or a treating oncologist’s judgement. Results must be interpreted by an RGCC-accredited practitioner in the context of the full medical history. RGCC circulating tumor cell (CTC) assays are not designed to detect primary cancers of the brain or central nervous system. Always discuss findings with your own doctor before changing any treatment.